

Original Research Article

Comparing the Efficacy of Carvedilol and Celecoxib to Prednisolone in Acetic Acid-Induced Ulcerative Colitis in Male Albino Rats.

Abstract

Ulcerative colitis refers to destruction of mucosal layer of distal colon and rectum. The exact mechanism for pathophysiology of the disease is still unclear but inflammation and oxidative stress may play a caustic role. Neutrophil and monocyte infiltration results in free radical generation which damages intestinal mucosa as a result of immune and inflammatory reactions. Many treatments including steroids are used to reduce inflammation but cannot be used to allow remission. Carvedilol is a third-generation nonselective β -blocker which possesses anti-apoptotic and anti-inflammatory properties and can be used to reduce gastric ulceration. Celecoxib is a selective cyclooxygenase -2 (COX-2) inhibitor which is associated with decreased risk of gastrointestinal bleeding. The current study was designed to compare the efficacy of carvedilol and celecoxib to prednisolone in acetic acid-induced ulcerative colitis model. A total of 40 adult male albino rats were used in the study and randomly divided into five groups as follows; Control group: Rats received 2 ml of saline transrectally. Acetic acid (AA) group: Rats were intrarectally injected with 2ml acetic acid. Prednisolone+AA group: Rats were pre-treated with prednisolone in a dose 4mg/kg /day. Carvedilol+AA group: Rats were pre-treated with carvedilol in a dose 30 mg/kg/day. Celecoxib+AA group: Rats were pre-treated with celecoxib in a dose 5mg/kg/day. All drug treatments were given orally for 7 days. At end of the experiment, distal colon was removed where one part of specimen was preserved in 10% formalin for histological examination and the other part was homogenized and kept at -20°C for evaluation of biological parameters such as tumor necrosis factor alpha (TNF- α), reduced glutathione (GSH), malondialdehyde (MDA), nitric oxide (NO) and mitogen-activated protein kinase (p38 MAPK). Data of the present study revealed that treatment of rats with carvedilol or celecoxib before induction of colitis significantly reduced the elevation of MDA, NO, TNF- α , mRNA levels of p38 MAPK due to acetic acid while both drugs increased the values for GSH. Also, both drugs

preserved the structure of the colon , reduced perforation , ulceration and decreased cytoplasmic COX-2 expression in colon tissue. The protective effect of carvedilol and celecoxib is attributed to their anti-inflammatory and oxidative stress reducing ability. Their ability to decrease the synthesis of MAPK will reduce signaling of cytokines within the epithelial cells of the gut mucosa.

Keywords: ulcerative colitis, celecoxib, carvedilol, anti-inflammatory, oxidative stress, P38 MAPK

1.Introduction:

Ulcerative colitis (UC) is an inflammatory bowel disorder characterized by damage to mucosal layer of the distal part of colon and rectum ^[1,2]. The disease leads to disturbance in homeostasis in the digestive tract and intestinal inflammation ^[3]. Symptoms include diarrhea, abdominal cramps and recurrent blood in the stools due to mucosal ulcers ^[4]. The exact cause of UC is still unknown, but many factors may contribute to its pathogenesis, including genetic susceptibility, environmental factors and imbalance between the immune system and the intestinal microbes ^{[5],[6]}. Also, oxidative stress and inflammation play a causative role in the pathogenesis of UC because neutrophils and monocytes infiltration results in high amounts of oxygen free radicals that leads to inflammatory and immune responses which damages intestinal epithelial cells and affects mucosal integrity ultimately leading to UC ^{[7],[8]}.

Prednisolone belongs to steroid drugs. Regarding treatment of inflammatory bowel disorders, steroidal drugs are used to reduce inflammation and allow bowel healing. Previous studies have shown that steroids can help controlling active UC, but do not maintain remission state and therefore, cannot be used as long-term maintenance therapy to prevent relapse ^[9].

Carvedilol is a third-generation nonselective β -blocker that is used as antihypertensive drug and also in treatment of myocardial infarction ^[10]. Carvedilol possesses both anti-apoptotic and anti-inflammatory properties ^[11] with mitochondrial protection ability ^[12]. It can also inhibit lipid peroxidation ^[13]. In addition, it was found to reduce gastric secretion and ulceration owing to its antioxidant activity ^[14].

Celecoxib is a nonsteroidal anti-inflammatory drug that belongs to selective cyclooxygenase-2 (COX-2) inhibitors. It is associated with decreased risk of gastrointestinal bleeding ^[15]. COX-2 is expressed in inflamed tissues due to

induction by inflammatory mediators ^[16]. COX-2 enzyme inhibition decreases the synthesis of prostaglandin E2 (PGE2), prostacyclin (PGI2), thromboxane (TXA2), prostaglandin D2 (PGD2), and prostaglandin F2 (PGF2) which leads to alleviation of pain and inflammation ^{[16],[17]}.

Acetic acid-induced ulcerative colitis is a simple model which is similar to human ulcerative colitis. High concentrations of acetic acid cause perforations of the colon. The use of 4% acetic acid through intrarectal administration causes inflammation and ulceration of the colon without perforation ^[18].

This study aimed to investigate the potential protective effects of carvedilol and celecoxib compared to prednisolone as standard drug against acetic acid-induced ulcerative colitis.

2. Materials and Methods:

2.1 Chemicals:

Acetic Acid was purchased from Sigma Company, Cairo, Egypt. Carvedilol was purchased as 25mg tablets from Multi Apex Pharma, Egypt. Each tablet was dissolved in 5ml saline, so 1ml of the solution contained 5mg carvedilol. Celecoxib was purchased as 100mg capsule from Pfizer, Egypt. Each tablet was dissolved in 5ml saline, so 1ml of solution contained 20mg celecoxib. Prednisolone was purchased as 5mg tablets from Adco, Egypt. Each tablet was dissolved in 5ml saline, so 1ml of the solution contained 1mg prednisolone.

2.2 Animals & grouping:

In this study, 40 adult male albino rats of average weight (150-200 grams each), aging 3-4 months were used and maintained under specific clean conditions in the animal house of Faculty of Medicine, Tanta University. The rats were housed in plastic cages with free access to food ad libitum and water. All experimental procedures described in this study comply with the ethical principles and guidelines for care and the use of laboratory animals adopted by the "Research Ethics Committee" Faculty of Medicine, Tanta University (NIH publication NO.8023, revised 1978) to minimize animal suffering. The study was approved on 14/03/2021. Animals were allocated into different groups.

2.3 Induction of UC:

All rats were fasted for 24h with free access to water. After light anesthesia with ether, colitis was induced by instillation of 2ml acid acetic solution (3% in normal saline) using a polyethylene tube which was introduced into the anus to a distance of 8 cm. The rats were then maintained in the head-down position for 30 second to prevent leakage of the acetic acid. Induction of UC was done according to the method described by Mousavizadeh et al. ^[19]. Control group received intracolonic equal volume of normal saline instead of acetic acid with the same procedure.

2.4 Experimental design:

Animals were randomly divided into five groups with eight rats in each group as follow;

Group I (Control): Rats received transrectal injection of a single dose of 2ml of physiological saline and kept for the same periods as experimental animals.

Group II (AA): Rats were injected with 2ml acid acetic solution intrarectally.

Group III (Prednisolone+AA): Rats were pre-treated with prednisolone in a dose 4mg/kg /day orally for seven days. ^[20] Each rat with average weight 180mg received 0.75ml of prednisolone dissolvent before the induction of UC.

Group IV (Carvedilol + AA): Rats were pre-treated with carvedilol in a dose 30 mg/kg/day orally for seven days. ^[10] Each rat with average weight 180mg received 1ml of carvedilol dissolvent before the induction of UC.

Group V (Celecoxib+AA): Rats were pre-treated with celecoxib in a dose 5mg/kg/day orally for seven days. ^[21] Each rat with average weight 180mg received 0.5ml of celecoxib dissolvent before the induction of UC.

At end of the experiment, all animals were anaesthized with suitable amount of ether and then sacrificed at the optimum time. The distal colon (5-6 cm) was rapidly removed and gently washed from fecal content using normal saline. One part of specimen was preserved in 10% formalin for histological examination. The other part was homogenized and kept at -20⁰C for evaluation of biological parameters such as TNF- α , reduced glutathione, MDA and Nitric oxide.

2.5 Biochemical Assays:

All biochemical measurements were performed in pharmacology department, Faculty of medicine, Tanta university.

2.5.1 Determination of gastric tissue malondialdehyde (MDA) content (nmol/gm tissue):

Malondialdehyde was determined according to the colorimetric method of ^[22]. The principle of the assay is based on interaction between thiobarbituric acid (TBA) and MDA in acidic medium at temperature of 95°C for 30 min to form thiobarbituric acid reactive product and the absorbance of the resultant pink product can be measured at 534 nm. The absorbance of sample (A sample) was measured against blank.

2.5.2 Determination of nitric oxide (NO) content (nmol/gm tissue):

Nitric oxide concentrations in colonic tissues were measured by the Griess reaction method ^[23] using a commercially available kit (R & D Systems, Minneapolis, MN). Results were expressed as nM/gm tissue for NO.

2.5.3 Determination of tissue tumor necrosis factor alpha (TNF- α)content (pg/ml):

TNF- α was assayed using kit obtained from Sunred Biotechnology Company, Shanghai, China, according to the method of ^[24]. TNF- α was measured in gastric tissue homogenate. The kit uses a double-antibody sandwich ELISA to assay the level of rat TNF- α in samples. This assay measures the amount of antigen between two layers of antibodies (i.e. capture and detection antibody). The antigen is immobilized, usually in 96-well plates. Then, the antigen binds to a specific antibody, which is subsequently detected by a secondary, enzyme-coupled antibody. A chromogenic substrate for the enzyme yields a visible color change, indicating the presence of antigen. The chroma of color and the concentration of antigen in the sample are positively correlated.

2.5.4 Determination of tissue reduced glutathione (GSH) content (mg/g.tissue)

Reduced glutathione was determined according to the colorimetric method of ^[25] using kits supplied by Biodiagnostic company, Egypt. The principle of the methods depends on the fact that glutathione (GSH) reduces 5,5` dithiobis (2- nitrobenzoic acid (DTNB) to produce a yellow compound. The reduced chromogen is directly proportional to GSH concentration and its absorbance can be measured at wavelength of 405 nm.

2.5.5 Determination of mRNA levels of p38 MAPK:

Examination of MRNA levels of p38 MAPK in rat colon tissues was done using reverse transcription-polymerase chain reaction (RT-PCR). The total RNAs in the colon tissues of rats were extracted by TRIZol (Invitro-gen, Carlsbad, CA, USA)

lysis assay and reversely transcribed into complementary deoxyribose nucleic acids (cDNAs) according to the instructions of the first-strand cDNA kit (TaKaRa, Otsu, Shinga, Japan). Subsequently, PCR amplification was carried out on a PCR instrument. The sequences of the primers added are shown in **Table 1**. Reaction system: annealing at 65°C and extension at 72°C for 30 cycles. The reaction product was subjected to gel electrophoresis, and the optical density value was analyzed under a gel instrument^[26].

Table 1: Primer sequence for p38 MAPK

	Primer Sequence (5' →3')
P 38 MAPK Sense	F: AGGGCGATGTGACGTTT
Antisense	R: CTGGCAGGGTGAAGTTGG

2.6 Histopathological examination of colon tissues

Haematoxylin and Eosin (H&E) stain was done for detection of the general histological structure of rat's colon^[27]. **Table 2** shows scoring of histopathological results.

Table 2: Scoring of histopathological results

Score	Inflammation	Goblet cell loss	Glandular hyperplasia	Muscle thickening	Ulceration
0	None	None	None	None	Absent
1	Individual cells	Less than 10%	Slight increase	slight	
2	Mild Infiltrate	10-50%	2-3 folds increase	strong	
3	Large infiltrate	More than 50%	More than 3 folds increase	excessive	Present

2.7 Immunohistochemical detection of cyclooxygenase-2 (COX-2):

Four micron thick tissue was mounted onto poly L-lysine-treated Probe. Slides were deparaffinized and rehydrated. Endogenous peroxidases were degraded by incubating the sections in 0.5% hydrogen peroxide in methanol for 20 minutes. After a 15 minute wash in 0.01 M phosphate-buffered saline (PBSB) with 0.4% Brij, pH 7.2, the tissues were microwaved at high power for two sets of 10 minutes each in 0.1 M citrate buffer, pH 6.0. The tissues were rinsed in PBSB for 15 minutes and then incubated in 10% non-immune goat serum at room temperature for 20 minutes. A rabbit polyclonal antibody to COX-2 (PG27B, Oxford Biomedical Research, Oxford, MI) diluted 1: 100 in PBS, was applied, and the sections were incubated overnight at 4 C. After rinsing in PBSB for 15 minutes, the bisotinylated secondary antibody diluted 1: 200 in PBS was applied, and the sections were incubated at room temperature for 45 minutes. After a 15 minute rinse in PBSB, RTU Elite ABC reagent (Vectastain PK-7100, Vector) was applied and incubated at room temperature for 45 minutes. The antibody reaction products were observed with the chromagen 3,3-diaminobenzidine tetrahydrochloride (DAB, 71-00-08, Kirkegaard and Perry Lab, Gaithersburg, MD) and counterstained briefly with Gill's hematoxylin. Negative control tissues were treated similarly except that normal nonimmune rabbit serum, used as a nonspecific antibody control, was substituted for the COX-2 antibody [28]. COX-2 immunolabelling was evaluated by a semi-quantitative assessment which included staining grade (percentage of positive cells) and intensity. Five 10X fields from each slide were evaluated. The grade (percentage) was evaluated by the following scoring system: 0 = negative; 1 = < 10% of cells staining positive; 2 = 10–30%; 3 = 31–60%; 4 = > 60%. Intensity was evaluated by the following scoring system: 0 = negative; 1 = weak staining; 2 = moderately intense staining; and 3 = marked intense staining. Intensity of positive control cells was considered marked staining. The final expression score was calculated multiplying the intensity with percentage and classified as weak (1–2), moderate (3–5), marked (6–8) and very marked (> 9).

2.8 Statistical analysis:

All data assessed were statistically analyzed using SPSS software version 13 (SPSS Inc., Chicago, IL, USA), then compared by one way analysis of variance

(ANOVA). The results were expressed as mean±standard deviation (SD). The differences were considered statistically significant if probability value $P < 0.05$.

3.Results

As presented in **Figure 1**, induction of ulcerative colitis in rats resulted in significant increase (129%) in MDA tissue contents compared to control group. On the other hand, pretreatment with prednisolone significantly decreased (42.6%) tissue MDA contents compared to acetic acid group. Pretreatment with carvedilol and celecoxib resulted in significant decrease in tissue MDA contents (30% and 27%, respectively) compared to acetic acid group and (25% and 30%, respectively) compared to prednisolone group.

Similarly, acetic acid resulted in significant increase (119%) in NO tissue contents compared to control group. On the other hand, pretreatment with prednisolone significantly decreased (28%) tissue NO contents compared to acetic acid group. Pretreatment with carvedilol and celecoxib resulted in significant decrease in tissue NO contents (25% and 16%, respectively) compared to acetic acid group and (26% and 42%, respectively) compared to prednisolone group (**Figure 2**).

Figure 3 shows that induction of colitis caused a significant elevation of tissue TNF- α content (30%) compared to control group and prednisolone significantly reduced TNF- α content (16%) compared to acetic acid group. Furthermore, pretreatment with carvedilol and celecoxib significantly reduced tissue TNF- α content (31% and 20%, respectively) compared to acetic acid group and (27% and 47%, respectively) compared to prednisolone group.

As shown in **Figure 4**, induction of ulcerative colitis in rats resulted in significant decrease (49%) in GSH tissue contents compared to control group. On the other hand, pretreatment with prednisolone significantly increased (76%) tissue GSH contents compared to acetic acid group. Pretreatment with carvedilol and celecoxib resulted in significant increase in tissue GSH contents (47% and 24%, respectively) compared to acetic acid group and (16% and 29%, respectively) compared to prednisolone group.

Figure 5a shows that induction of colitis caused a significant increase in mRNA levels of p38 MAPK (243%) compared to control group and prednisolone significantly reduced mRNA levels of p38 MAPK (58%) compared to acetic acid group. Furthermore, pretreatment with carvedilol and celecoxib significantly reduced tissue

mRNA levels of p38 MAPK (51% and 38%, respectively) compared to acetic acid group and (17% and 48%, respectively) compared to prednisolone group.

Histopathological examination of normal colon tissue revealed normal colonic mucosal glands with average in size and shape showing goblet cells (**Figure 6a**). Induction of ulcerative colitis by acetic acid resulted in sub-mucosal infiltration of chronic inflammatory cells with hyperplasia, excessive thickening and ulceration (**Figure 6b-d**). Pretreatment with prednisolone significantly reduced inflammation and infiltration of hyperplastic gland with no loss of goblet cells (**Figure 6e**). On the other hand, treatment of rats with carvedilol showed mild infiltration of inflammatory cells and decreased scores of hyperplastic glands with no loss of goblet cells (**Figure 6f**). Similarly, celecoxib decreased the scores of inflammatory cells and hyperplastic glands but to a lesser extent (**Figure 6g**).

Immunohistochemical staining for COX-2 expression in colon tissue showed strong positive staining for COX-2 in acetic acid group compared to control group (**Figure 7b**). Treatment of animals with prednisolone showed weak cytoplasmic COX-2 positivity (**Figure 7c**) while pretreatment with carvedilol showed moderate cytoplasmic COX-2 positivity (**Figure 7d**) and pretreatment with celecoxib showed marked cytoplasmic COX-2 positivity (**Figure 7e**).

4. Discussion:

In the present study, acetic acid-induced ulceritis resulted in significant elevation of oxidative stress markers (MDA and NO) together with significant reduction in antioxidant GSH content in colonic tissue. Ulcerative colitis belongs to inflammatory bowel diseases that affect millions of people all over the world. The etiology of such diseases remain unknown but recent studies have suggested that excessive activation of immune system targeting the gut micro biota play pivotal role ^[29,30]. We suggest that activation of the mucosal immune system results in an inflammatory state accompanied by dysregulation of the cytokine system which in turns activate oxidative stress and release of free radicals. Gastrointestinal tract (GIT) is a major site for reactive oxygen species (ROS) generation due to the presence of microbes and food

ingredients. This may decrease the antioxidant capacity of the patient and excessive generation of oxidative stress markers enhances lipid peroxidation and depletes antioxidant defense. This suggestion is supported by the observation that ulceritis was associated with significant increase in the intestinal content of the pro-inflammatory cytokine TNF- α in the current study.

We observed that administration of prednisolone significantly reduced the elevation in MDA and NO together with significant elevation in GSH. These observations indicate that prednisolone possesses an antioxidant potential. Prednisolone as a standard therapy to inflammatory bowel diseases is well known to reduce the inflammation and allow bowel to heal. However, steroids are not recommended for long term treatment due to their unfavorable side effects and their inability to inhibit flare-ups so, there is an emergent need to reduce or stop steroids or move to alternative medications ^[31,32,33]

The data of the present study revealed that carvedilol possesses a more effective antioxidant potential compared to prednisolone as indicated by more significant reduction in MDA, NO and more significant elevation in GSH tissue contents compared to prednisolone. To our knowledge, this is the first study to test the effectiveness of carvedilol in acetic acid-induced ulcerative colitis model. In line with our observations, it was found that nebivolol, a long-acting, third-generation, selective β 1-adrenoceptor antagonist exhibited antioxidant effect as shown by normalizing the values for serum contents of thiobarbituric acid reactive substances (TBARS), TNF- α and interleukin-1 β (IL-1 β) and superoxide dismutase (SOD) activity ^[35]. We suggest that the inhibitory effects of carvedilol on lipid peroxidation are due to its antioxidant activity and its ability to suppress inducible nitric oxide synthase (iNOS) expression. The third-generation, selective β 1-adrenoceptor antagonist including carvedilol and nebivolol promote nitric oxide (NO-induced) vasodilatation through endothelial nitric oxide synthase (eNOS) -mediated β 3- adrenoceptor activation ^[35]. They act as antioxidants through inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, subsequent SOD reduction and prevention of eNOS uncoupling ^[36]. The results of the current study indicated that the antioxidant capacity of the damaged mucosa is compromised thus; the use of non-traditional therapy as antioxidants will inhibit the cell damage and improves the activity of antioxidant defense.

Some studies have reported that blocking β -adrenoceptor has an anti-inflammatory effect and was associated with decreased levels of pro-inflammatory cytokines [37]. Carvedilol was the first third-generation β -blocker which exhibits antioxidant activity. Its antioxidant property is due to its carbazole moiety [38,39]. Carvedilol exhibited antioxidant effects by reducing superoxide production by inhibiting NADPH oxidase and preventing eNOS uncoupling. Another possible mechanism is acting within the mitochondria as ROS scavenger thus inhibiting superoxide anion or hydrogen peroxide.

In the present study, pretreatment of rats with carvedilol significantly decreased TNF- α level. This is similar to previous studies which showed that a similar drug, nebivolol significantly decreased TNF- α in ulcerative colitis model, in human umbilical vein and in human coronary sites [40,41,42].

Similarly, the results for celecoxib pre-treated group showed that it significantly decreased MDA, NO, TNF- α and significantly increased GSH levels compared to prednisolone group. These results are in agreement with previous data which showed that celecoxib caused a substantial reduction of the degree of colonic injury, the rise in myeloperoxidase and the increase in the tissue levels of malondialdehyde in dinitrobenzene sulfonic acid (DNBS)-induced colitis [21]. The function of cyclooxygenase-1 and cyclooxygenase-2 in maintaining mucosal homeostasis and modulating inflammation in the digestive tract remains unclear. Prostanoids are increased in experimental colitis and in inflammatory bowel disease [43,44]. Therefore, they play a protective role in colitis and down regulate the expression of proinflammatory cytokines. It was hypothesized that inducible cyclooxygenase-2 drives the pro-inflammatory actions of prostaglandins during mucosal injury. Thus, the gastro protective effects of celecoxib arise from its ability to inhibit COX-2 and its anti-inflammatory effect while avoiding gastrointestinal (GI) toxicity. Our results indicate that celecoxib is effective in modulating the extent of experimental colitis.

The pathogenesis of ulcerative colitis is closely associated with elevated TNF- α and interleukin-1 β content as they are present in colon mucosa and can be detected in inflamed tissues. So that, preventing of the action of these cytokines suppresses inflammation and reduces colon destruction that corresponds to the anti-inflammatory effect of celecoxib. In the present study, the increased TNF- α in colon tissue was

reduced by celecoxib. In addition, treatment with celecoxib markedly reduced the cellular infiltrate in the colon and the inflammation of colon tissue. The ability of COX-2 inhibitors to reduce the inflammatory cell infiltrate in the colon could in part explain the observed reduction in the expression levels of COX-2 and cytokine production.

Neutrophils have been considered to play a crucial role in the development of GI inflammation, as they are the major source of free radicals in the inflamed mucosa [45,46]. Colonic inflammation is associated with infiltration of polymorphonuclear leukocytes, thus activation of neutrophils may be a major source of ROS and NOS species. In the present study, we found that mucosal damage induced by acetic acid is associated with significantly high levels of MDA. This is a good indicator of lipid peroxidation. The epithelial disruption was significantly reduced in rats pretreated with celecoxib and this was associated with decreased tissue MDA, significant resolution of histological signs of inflammation.

In a previous meta-analysis, it was found that Coxibs are safe in patients with inflammatory bowel disease (IBD) compared to NSAIDs in patients suffering from rheumatic pain resistant to standard treatment [47]. Another study revealed that short-term treatment with celecoxib up to 14 days did not possess a greater clinical and endoscopic relapse rate compared to placebo in patients with ulcerative colitis [48]. Also, it was found that celecoxib and etoricoxib do not augment IBD symptoms [49].

We showed by immunohistochemistry that COX-2 is expressed in mucosal epithelial cells in rats received acetic acid and this expression was significantly decreased by the use of celecoxib.

The present data indicates that ulcerative colitis induced a significant increase in mRNA levels of p38 MAPK as revealed by PCR. It is well known that MAPK enzyme family is involved the cytokine signal transduction within the epithelial cell of the gut mucosa. They are activated via phosphorylation which in turn activates specific transcription factors and subsequent target genes. So, there should be therapeutic regimes directed towards cytokine signaling pathways [50]. We showed that both celecoxib and carvedilol significantly reduced mRNA levels of p38 MAPK compared to ulcerative colitis group and to prednisolone. By inhibiting the p38 MAPK, celecoxib and carvedilol can effectively suppress the production of cytokines (e.g. TNF- α , IL-1,

IL-2 and IL-6). These data indicate that both drugs may act as inhibitors of p38 kinase. The inhibition of the activity of MAPK is further confirmed by significant reduction of TNF- α release in both carvedilol and celecoxib pre-treated groups. This also sheds more light on the importance of MAPK in the pathophysiology of colitis. To our knowledge, this is the first study to explore the role of celecoxib and carvedilol in regulating MAPK pathway in ulcerative colitis model.

The results of the present study are in agreement with previous studies which explored the regulation of MAPK/ERK/JNK signaling pathway in ulcerative colitis. It was found that chlorogenic acid reduces dextran sulfate sodium (DSS)-induced ulcerative colitis in mice, which can significantly reduce tissue inflammation and apoptosis. This action is through MAPK/ERK/JNK signaling pathway^[51].

The key roles of p38 MAPK in IBD obviously lay both in the immune and non-immune cells. First, p38 MAPK up regulates the expression of some genes involved in intestinal inflammation, such as genes coding for TNF- α , IL-1, IL-6, IL-8, cyclooxygenase-2, collagenase-1 and collagenase-3. Meanwhile, non-immune cells, like human intestinal microvascular endothelial cells (HIMEC), intestinal epithelium, fibroblasts and myofibroblasts, are involved in IBD and are under control of the direct and indirect effect of p38 MAPK^[52]. In the present study, the reduction of the expression of COX-2 by pre administration of celecoxib or carvedilol could be also in part due to inhibition of p38 MAPK.

In addition, the increased activation of MAPK in the current study plays a major role in promoting apoptosis. This was evident by increased apoptosis in tissue samples from ulcerative colitis groups. Activated p38 MAPK induces the recruitment and activation of lymphocytes and neutrophils and delays the apoptosis of these immune cells in ulcerative colitis. The activation of p38 MAPK also regulates the adhesion and transmigration of lymphocytes across the microvasculature via the up regulation of vascular cell adhesion protein 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). On the other hand, the inhibition of p38 MAPK leads to decreased leukocyte recruitment in the inflamed GI^[53]. Through their inhibiting action on p38 MAPK, both celecoxib and carvedilol could decrease inflammatory cell recruitment to the colonic tissue and increase the structural integrity of the mucosa.

In the normal intestinal mucosa, macrophages are the major antigen presenting cell population as they determine the T-cell responses. However, they lack the capacity of mediating inflammatory responses. In case of UC and crohn's disease (CD), circulating monocytes migrate from the intravascular lumen to the inflammatory intestinal tissues and are converted to activated macrophages. These cells can mediate mucosal inflammation via the upregulation of gene expression of TNF- α , IL-1, IL-6, IL-8, COX-2, collagenase-1 and collagenase-3. p38 MAPK inhibitors can reduce the expression of these genes selectively^[54]. TNF- α and IL-1 can in turn activate p38 MAPK, forming a vicious cycle in the development of inflammatory response^[55]. The administration of both carvedilol and celecoxib was associated with decreased intestinal damage, mitochondrial swelling, reactive oxygen species, and MAPK, which indicate that both drugs can reduce mitochondrial damage by improving intestinal mitochondrial ultrastructure. The results of the experiment showed that both drugs can significantly improve tissue damage, reduce inflammatory factors, and increase the expression of anti-inflammatory factors, indicating that these drugs have protective effects on acetic acid -induced ulcerative colitis.

5. Conclusion

the data of the present study revealed that both celecoxib and carvedilol have protective effects on acetic-acid induced ulcerative colitis and their effects are due to anti inflammatory, antioxidant effects and their ability to suppress p38 MAPK.

6. References

1. Ikeda Y, Akba F, Matsui H et al. Characterization of antigen-presenting dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis. *Eur.J. Gastroenterol. Hepatol* 2001; 13: 841–850.
2. Howell HR. Ulcerative Colitis: Achieving and Maintaining Remission. *US Pharm* 2008;33(12):30-37.
3. Baumgart DC and Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 2007; 369:1641–1657.
4. Xavier RJ and Podolsky DK. Unravelling the pathogenesis of inflammatory

bowel disease. *Nature* 2007; 448:427–434.

5. Seregin S, Golovchenko N, Schaf B et al. NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury. *Mucosal Immunology* 2017; 10: (2):434 – 445.
6. Kayali S, Gaiani F, Manfredi M et al. Inverse association between *Helicobacter pylori* and inflammatory bowel disease: myth or fact?. *Acta. Bio. Medica. Atenei. Parmensis.* 2018; 89(9-S):81-86.
7. Kurutas EB, Cetinkaya A, Bulbuloglu E et al. Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. *Mediators Inflamm* 2005;390–394.
8. Oz HS, Chen TS, McClain CJ et al. Antioxidants as novel therapy in a murine model of colitis. *J Nutr Biochem.* 2005; 16:297–304.
9. <https://www.buckshealthcare.nhs.uk>.
10. Fatani AJ, Al-Hosaini KA, Ahmed MM et al. Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis. *Drug Dev Res.* 2015; 76(4):204-214.
11. Le DE, Pascotto M, Leong-Poi H, et al. Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. *Basic Res Cardiol* 2013; 108 (6): 384-407.
12. Rodrigues MA, Rodrigues JL, Martins NM et al. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. *Chem Biol Interact* 2011;189: 45– 51.
13. Hakucho A, Liu J, Liu X, et al. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. *Hepatol Res* 2014; 44: 560– 570.
14. AlRejaie SS. Inhibition of ethanol induced gastric mucosal damage by Carvidolol in male Wistar albino rats: possible biochemical changes. *Int J*

Pharmacol 2009; 5: 146– 154.

15. Shin S. Safety of celecoxib versus traditional nonsteroidal anti-inflammatory drugs in older patients with arthritis. *J Pain Res.* 2018; 14(11):3211-3219.
16. Arslan A, Yet B, Nemutlu E, Akdağ Çaylı Y, Eroğlu H, Öner L. Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. *Pharmaceutics.* 2023 (2):15(2):363.
17. Gong L, Thorn CF, Bertagnolli MM, et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics* 2012; 22(4):310-318.
18. Dugani A, Dakhil B and Treesh S. Protective effect of the methanolic extract of malva parviflora leaves on acetic acid-induced ulcerative colitis in rats. *Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association* 2016; 22(3):226-233.
19. Mousavizadeh K, Rahimian R, Fakhfouri G et al. Anti-inflammatory effects of 5-HT receptor antagonist, Tropicsetron on experimental colitis in rats. *Eur J Clin Invest* 2009; 39: 375-383.
20. Sadraei H, Asghari G, Khanabadi M et al. Anti-inflammatory effect of Apigenin and hydroalcoholic extract of *Dracocephalum kotschyi* on acetic acid-induced colitis in rats. *Res Pharm Sci.* 2017;12(4):322-329.
21. Cuzzocrea S, Mazzon E, Serraino I, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. *Eur J Pharmacol.* 2001;431(1):91-102.
22. Ohkawa H, Ohishi N and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Analytical biochemistry* 1979; 95(2): 351-358.
23. Bryan NS and Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. *Free Radic Biol Med.* 2007;43(5):645-657.
24. Chai SK. Rational choice and culture: clashing perspectives or complementary modes of analysis? In: Ellis RJ and Thompson M (eds.) *Culture matters.*

Boulder, CO: Westview Press, 2018, pp 45-56.

25. Beutler E. Improved method for the determination of blood glutathione. *J Lab Clin Med* 1963; 61: 882-888.
26. Bai XS, Bai G, Tang LD et al. MiR-195 alleviates ulcerative colitis in rats via MAPK signaling pathway. *Eur Rev Med Pharmacol Sci* 2020;5:2640-2646.
27. Drury R and Willington EA. Carletons histological techniques. In (Wallington EA (eds). 8th edition, Oxford University Press, New York, Toronto, 1980, pp 195-205.
28. Beam SL, Rassnick KM, Moore AS et al. An immunohistochemical study of cyclooxygenase-2 expression in various neoplasms. *Veterinary pathology* 2013; 40(5): 496-500.
29. Ohno M, Nishida A, Sugitani Y et al. Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. *PLOS one* 2017; 12(10): e0185999
30. Podolsky DK. Inflammatory bowel disease. *The New England journal of medicine* 2002; 347(6): 417–29.
31. Carter MJ, Lobo AJ, Travis SPL et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2004;53(Suppl V):v1–v16.
32. Gionchetti P et al. Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Digestive and Liver Disease* 2017; 49: 604–617.
33. Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001;121:255–260
34. Labiba DA, Shakerb OG and Elfarouk LO. Protective effects of nebivolol on acetic acid-induced ulcerative colitis in rats. *Kasr Al Ainy Medical Journal* 2016; 22:99–108.

35. Gupta S and Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. *Cardiovasc Ther* 2008; 26:189–202.
36. Münzel T and Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. *J Am Coll Cardiol* 2009; 54:1491–1499
37. Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1 β and MMP-8 expression and a modulated immune response. *European journal of heart failure* 2005; 7(4): 444-452.
38. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. *J Pharmacol Exp Ther* 1992; 263:92–98.
39. Hess ML and Varma A. The third-generation beta-blocker: have we found the elusive, effective antioxidant?. *J Cardiovasc Pharmacol* 2013; 62:443–444.
40. Wolf SC, Sauter G, Jobst J, et al. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. *Int J Cardiol* 2008; 125:4–10.
41. Morsy MA and Heeba GH. Nebivolol ameliorates cisplatin-induced nephrotoxicity in rats. *Basic Clin Pharmacol Toxicol* 2016
42. Garbin U, Fratta Pasini A, Stranieri C et al. Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. *Mediators Inflamm* 2008; 2008:367590
43. Rachmilewitz D, Simon PL, Schwartz, LW, et al. Inflammatory mediators of experimental colitis in rats. *Gastroenterology* 1981;97:326–32
44. Sharon P, Ligumsky M, Rachmilewitz D et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine. *Gastroenterology* 1978;75, 638– 640
45. Grisham MB. Oxidants and free radicals in inflammatory bowel disease.

Lancet 1994; 344, 859–861

46. Shiratora Y, Aoki, S, Takada H., Kiriyaama H., et al. Oxygenderived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. *Digestion* 1981;44, 163–171.
47. Ribaldone DG, Fagoonee S, Astegiano M et al. Coxib Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis. *Pain Physician* 2015; 18:599-607
48. Sandborn WJ, Stenson Wf, Brynskov J et al. Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study. *Clinical Gastroenterology and Hepatology* 2006;4:203–211
49. Miao X, Li J, Ouyang Q et al. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. *Cochrane Database of Systematic Reviews*. 2014; 10. CD007744
50. Arulampalam V and Pettersson S. Uncoupling the p38 MAPK kinase in IBD: a double edged sword?. *Inflammation and inflammatory bowel disease. Gut* 2002; 50:444-446.
51. Gao W, Wang C, Yu L et al. Chlorogenic Acid Attenuates Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice through MAPK/ERK/JNK Pathway. *BioMed Research International* 2019; Article ID 6769789.
52. Feng Y and Li Y. The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease. *Journal of Digestive Diseases* 2011; 12: 327–332
53. Scaldaferrri F, Sans M, Vetrano S et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. *Eur J Immunol* 2009; 39: 290–300.
54. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. *Inflamm Bowel Dis* 2000; 6: 21–33.
55. Saklatvala J, Dean J, Clark A. Control of the expression of inflammatory




Figure 1: Comparison of tissue MDA content (nmol/g.tissue) in different groups .
Values are presented as mean±SD. n=8

* Significant difference from control group at $p < 0.05$

\$ Significant difference from AA group at $p < 0.05$.

Significant difference from Prednisolone group at $p < 0.05$.




Figure 2: Comparison of NO content (nmol/g.tissue) in different groups. Values are presented as mean±SD. n=8

* Significant difference from control group at $p < 0.05$

\$ Significant difference from AA group at $p < 0.05$.

Significant difference from Prednisolone group at $p < 0.05$.




Figure 3: Comparison of tissue TNF- α content (pg/ml) in different studied groups. Values are presented as mean \pm SD. n=8

* Significant difference from control group at $p < 0.05$

\$ Significant difference from AA group at $p < 0.05$.

Significant difference from Prednisolone group at $p < 0.05$.




Figure 4: Comparison of GSH (mg/g. tissue) in different groups. Values are presented as mean \pm SD. n=8

* Significant difference from control group at $p < 0.05$

\$ Significant difference from AA group at $p < 0.05$.

Significant difference from Prednisolone group at $p < 0.05$.




Figure 5: (a) Semiquantitative analysis of p38 MAPK in different groups in colonic tissue as determined by reverse transcription quantitative polymerase chain reaction. Values are presented as mean±SD. n=8 (b) PCR analysis of p38 MAPK in different groups.

* Significant difference from control group at $p < 0.05$

\$ Significant difference from AA group at $p < 0.05$.

Significant difference from Prednisolone group at $p < 0.05$.




Figure 6: Photomicrographs of colon tissue (H&E x 100) (a) Section of colon of normal animal (negative control) showing normal colonic mucosal glands, average in size and shape showing goblet cells (blue arrows) separated by fibroblastic stroma (b) acetic acid group showing sub-mucosal large infiltrate of chronic inflammatory cells score 3 (red arrows) with hyperplasia of glands score 2 and loss of goblet cells score 3(

blue arrows) (c) Section of colon in AA showing ulceration score 3 (blue arrow) surrounded by hyperplastic glands with loss of goblet cells score 3 (red arrows)(d) Section of colon in AA group showing excessive muscle thickening score 3 (blue arrow) surrounded by congested vessels (red arrows) with overlying colonic mucosa (e)Section of colon in prednisolone in animal showing individual chronic inflammatory cells infiltrate score 1 (red arrows) with hyperplastic glands score 1 (blue arrows) with no loss of goblet cells score 0 (f) Section of colon in carvedilol group showing mild infiltrate of chronic inflammatory cells score 2 (red arrows) with hyperplastic glands score 2 (blue arrows) with no loss of goblet cells score 0 (g) Section of colon in celecoxib group showing mucosal diffuse infiltrate of chronic inflammatory cells score 3 (red arrows) with hyperplastic glands score 2 (blue arrows) showing mild loss of goblet cells score 1 (green arrows)

UNDER PEER REVIEW




Figure 7: Photomicrographs for immunohistochemical expression of COX-2 in colon tissue (X100) (a) Section of colon in control group showing negative COX-2 immunoeexpression (b) Section of colon in acetic acid group showing very marked cytoplasmic COX-2 positivity (score 12) (c) Section of colon in prednisolone group showing weak cytoplasmic COX-2 positivity (score 2) (d) Section of colon in carvedilol group showing moderate cytoplasmic COX-2 positivity (score 4) (e) Section of colon in celecoxib group showing marked cytoplasmic COX-2 positivity